{"id":"NCT02706951","sponsor":"AbbVie","briefTitle":"A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)","officialTitle":"A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to MTX","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-23","primaryCompletion":"2017-10-02","completion":"2022-08-10","firstPosted":"2016-03-11","resultsPosted":"2019-10-07","lastUpdate":"2024-01-30"},"enrollment":648,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Methotrexate","otherNames":[]},{"type":"DRUG","name":"Upadacitinib","otherNames":["ABT-494","Rinvoq"]},{"type":"DRUG","name":"Placebo Upadacitinib","otherNames":[]},{"type":"DRUG","name":"Placebo Methotrexate","otherNames":[]}],"arms":[{"label":"Upadacitinib 30 mg","type":"EXPERIMENTAL"},{"label":"Upadacitinib 15 mg","type":"EXPERIMENTAL"},{"label":"Methotrexate / Upadacitinib 30 mg","type":"EXPERIMENTAL"},{"label":"Methotrexate / Upadacitinib 15 mg","type":"EXPERIMENTAL"}],"summary":"The study objective of Period 1 of this study is to compare the safety and efficacy (signs and symptoms) of upadacitinib 30 mg once daily (QD) alone and upadacitinib 15 mg QD alone versus continuing MTX alone adults with moderately to severely active rheumatoid arthritis (RA) with an inadequate response to MTX.\n\nThe study objective of Period 2 is to evaluate the long term safety, tolerability, and efficacy of upadacitinib 30 mg QD and 15 mg QD in adults with RA who had completed Period 1.","primaryOutcome":{"measure":"Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14","timeFrame":"Baseline and week 14","effectByArm":[{"arm":"Methotrexate","deltaMin":41.2,"sd":null},{"arm":"Upadacitinib 15 mg","deltaMin":67.7,"sd":null},{"arm":"Upadacitinib 30 mg","deltaMin":71.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":153,"countries":["United States","Argentina","Australia","Austria","Belgium","Bulgaria","Chile","Czechia","Estonia","Greece","Hungary","Israel","Italy","Japan","Mexico","Poland","Portugal","Puerto Rico","Romania","Russia","Serbia","South Africa","Spain","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["31130260","40875187","40350200","37982966","37945286","37308218","36794283","36754548","36715850","36125701","34636000","34041702","33313898","33115760","31610021"],"seeAlso":["https://www.rxabbvie.com/"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":216},"commonTop":["Urinary tract infection","Upper respiratory tract infection","Nasopharyngitis","Blood creatine phosphokinase increased","Bronchitis"]}}